Printer Friendly

RXi Pharmaceuticals partners with Iovance Biotherapeutics to study immuno-oncology therapeutics in solid tumors.

M2 PHARMA-May 14, 2018-RXi Pharmaceuticals partners with Iovance Biotherapeutics to study immuno-oncology therapeutics in solid tumors

(C)2018 M2 COMMUNICATIONS

Biotechnology company RXi Pharmaceuticals Corporation (NASDAQ:RXII) revealed on Friday the launch of a research collaboration with Iovance Biotherapeutics for solid tumors.

The potential synergies of RXi's novel sd-rxRNA therapeutic compounds and Iovance's autologous cell therapy based on tumor-infiltrating lymphocytes (TILs) will be explored preclinically for the use in the treatment of cancer.

According to Dr Geert Cauwenbergh, president and CEO of RXi Pharmaceuticals, Iovance to explore its proprietary TIL technology with the former's proprietary sd-rxRNA technology.

RXi will further investigate and expand the prior published data with TIL and sd-rxRNA products, which demonstrated potentially enhanced tumor killing activity of TIL, said Dr Geert Cauwenbergh.

This partnership may be able to improve potency of the TIL product and possibly broaden the applicability of TIL in other tumors types, added Dr Cauwenbergh.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 14, 2018
Words:162
Previous Article:Perrigo announces US FDA's Complete Response Letter of generic ProAir.
Next Article:Amryt signs contract with Aegerion Pharmaceuticals.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters